The author of this recent case study, Branko G. Celler, an Emeritus Professor at the University of New South Wales in Sydney, Australia, developed a particularly serious form of sarcoidosis in 2012. While sarcoidosis is a chronic disease characterized by the formation of granulomas in various organs, only a small portion of patients have cardiac involvement, which can lead to symptomatic conduction disturbances, ventricular arrhythmias, progressive heart failure and sudden death. Read more about his recovery with anti-mycobacterial antibiotics.

Have you reserved your spot for the Human Para Conference, Mycobacterial Implications in Crohn’s and Chronic Inflammatory Diseases, coming to Berkeley, CA on September 21st & 22nd? It’s not too late! Registration closes a week prior to the event, and a detailed agenda, abstracts and updated registration information have recently been added to the conference pages. Additionally, we are pleased to announce that portions of this activity have been approved for AMA PRA Category 1 Credit^TM.

The 2017 Human Paratuberculosis Foundation annual report is now available. Read about our first year in review, including a financial update.

Two new dates have been added to the Joint MAP Testing Study! Dr. Stuart Weg and Dr. J. Todd Kuenstner will draw the final 45 samples needed to complete Human Para’s inaugural MAP research project in August. If you are over the age of 18 and live in the New York City area, please consider participating in our study, either as a Crohn’s disease patient or a healthy control. We are seeking 15 Crohn’s patients and 30 healthy control subjects to donate a small amount of blood.

Several years ago, Dr. Roderick Chiodini was asked to write a chapter for a book detailing his experiences. Dr. Chiodini is the microbiologist that originally cultured MAP from a 12 year old girl with Crohn’s Disease. He went on to found the International Association of Paratuberculosis and was the leading figure during the 1980’s and 1990’s. The book was never published. The following draft is his story.

The recently published article describing the discovery of a MAP mutation that may lead to the development of a MAP vaccine for both animals and humans was received by our community with great interest. One of the researchers, Dr. William C. Davis, has provided Human Para with a summary of this highly technical article. A huge thanks to Dr. Davis and his colleagues for this piece, and for their contribution to MAP science.

Read the Article

The Fight for the Cure Golf tournament on May 17th was a fantastic success! Find out how many funds were raised for MAP research, and what Human Para is doing next. a huge THANK YOU to the Joly family and all of our volunteers who made this event a success.

The American College of Gastroenterology (ACG) recently released the 2018 Guidelines for the treatment of Crohn’s Disease (CD). Such guidelines can profoundly influence how practitioners treat CD and how younger physicians perceive CD pathophysiology. It is therefore intensely disappointing to read the ACG’s mistaken and blatantly unsupported conclusions in regard to mycobacteria and Atypical Mycobacterial Antibiotic Therapy (AMAT) for CD.

Read the Article

Human Para is pleased to announce our 2018 Conference: Mycobacterial Implications in Crohn’s and Chronic Inflammatory Diseases. On September 21 & 22, 2018, a group of dedicated researchers will bring their experience and expertise to Berkeley, California for a two-day conference. Featuring presenters and experts from across the globe, this conference has been specifically designed to explore the role that mycobacteria, particularly Mycobacterium avium spp. paratuberculosis (MAP), may play in Crohn’s disease, Type 1 diabetes, multiple sclerosis and other chronic conditions.

Read the Article